BCHE and Alzheimer disease: Although the multifactorial nature of disease points at the existence of a number of possible targets, the existing treatment for AD is based mainly on increasing the concentration of ACh by inhibiting the action of enzymes responsible for its hydrolysis, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), or using N-methyl-D-aspartate (NMDA) receptor antagonists; both directions are directed at the restoration of cognitive functions of patients and alleviating the symptoms of the disease.